Biocon reports 95% YoY decline in net profit, operating revenue up 15%

Biocon posted a 95% year-on-year decline in reported net profit to Rs 31 crore in the first quarter ended-June. However, the company claims to have on a l������-������-�������� ���������� booked a 65% increase in profit after tax, ���������� ������������������ ������ the one-time divestment gains it made in the same quarter a year ago from the sale of metabolic, oncology and critical care portfolio of its �������������� ������������������������ ���������� (������) business to Eris Lifesciences.

The company’s operating revenue for Q1FY26 grew 15% year-on-year to Rs 3,942 crore. EBITDA for the quarter was at Rs 829 crore, down from Rs 1,755 crore a year ago. However, the company said on a like-for-like basis taking into account BFI divestment gains, EBITDA was up 19%. EBITDA margin for the period was 21%, down from 38% in Q1 FY25.

“The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities,” said Kiran Mazumdar-Shaw, Chairperson, Biocon Group.


“With execution momentum across all businesses and expanded capacity through acquisitions in the US by Syngene and Biocon Generics, we are well-positioned to drive long-term value creation in FY26 and beyond,” said Shaw.

Biocon concluded its first equity fundraise since 2004 IPO, raising Rs 4,500 crores through a Qualified Institutions Placement (QIP) in June. The funds will be used to increase Biocon’s holding in Biocon Biologics and provide an exit to the private equity investors in Biocon Biologics, the company said.

The company’s API & generic formulations business reported 6% growth in revenue from operations to Rs 697 crore.

“Growth in the quarter was primarily driven by revenues from recent drug product launches, including liraglutide in the EU, and dasatinib and lenalidomide in the US, supported by higher volumes in our API business,” said Siddharth Mittal, CEO & Managing Director, Biocon.

“We remain focused on launching new products, including the commercialisation of liraglutide across key strategic markets,” he added.

Biocon Biologics started posted 18% year-on-year revenue growth, driven by robust demand across key markets.